University of Michigan

Toyota Jidosha Kabushiki Kaisha

Facebook, Inc.

Pharmablock Sciences (nanjing), Inc.

Jiangsu Ascentage Biomed Development Inc.

Liu Liu

Shaomeng Wang

Donna McEachern

Longchuan Bai

Duxin Sun

Chao-Yie Yang

Angelo Aguilar

Jeanne Stuckey

Xiaoqin Li

Jennifer Lynn Meagher

Arul M Chinnaiyan

Bing Zhou

Jianfeng Lu

Yujun Zhao

Irfan A Asangani

Ruijuan Luo

Xu Ran

Jianfang Chen

Haibin Zhou

Kentaro Oguchi

Rui Guo

Dirk John Stoop

Hao Yang

Jianyong Chen

Yang Hu

Hacer Karatas

Yi Sun

Ting Zhao

Bo Wen

Jin Li

Dajun Yang

Haiying Sun

Ming Guo

Yu Jing

Yunlong Zhou

Lingling Jiao

Minmin Yang

Denzil Bernard

Liyue Huang

Zhuo Chen

Liangyou Rui

Xu Qian

Xuyuan Dong

Rong Sheng

Donna McEachem

Canhui Zheng

Dengyou Zhang

Donna Mceachern

Donna Mceacherm

Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

Small molecule DCN1 inhibitors and therapeutic methods using the same

The present invention provides PRMT5 inhibitors of Formula (I), wherein Ris a non-hydrogen monovalent group; W is a direct bond or &#x2014;NH&#x2014;; T, U, and V are independently of each other selected from C and N; Ris H or a halo; m is 1 or 2; X is a carbon, a nitrogen, or an oxygen; Y is C or N; Z is a direct bond or a carbon; Ris H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group; n is 1 or 2; and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided. 

Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof

A method receives a first image set depicting a merging zone, the first image set including first image(s) associated with a first timestamp; determines, using a trained first machine learning logic, a first state describing a traffic condition of the merging zone at the first timestamp using the first image set; determines, from a sequence of states describing the traffic condition of the merging zone at a sequence of timestamps, using a trained second machine learning logic, second state(s) associated with second timestamp(s) prior to the first timestamp of the first state using a trained backward time distance; computes, using a trained third machine learning logic, impact metric(s) for merging action(s) using the first state, the second state(s), and the merging action(s); selects, from the merging action(s), a first merging action based on the impact metric(s); and provides a merging instruction including the first merging action to a merging vehicle.

Machine learning enhanced vehicle merging

The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer. 

Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R, R, R, R, R, R, R, R, R, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer. and &#xae;

5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors

Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

Covalent small molecule DCN1 inhibitors and therapeutic methods using the same

Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.

BET bromodomain inhibitors and therapeutic methods using the same

In one embodiment, a method includes rendering an image comprising a plurality of tags, wherein each tag is associated with a particular location within the image, and wherein at least two tags of the plurality of tags are aggregated into an aggregated tag, calculating for each tag the distance of the location of the tag from the location of every other tag of the image responsive to the first user changing a zoom level for the image, and updating the aggregated tag based on the calculated distance of the locations of the tags to each other such that if the change in zoom level is zooming in, then the updated aggregated tag is aggregated with at least one fewer tag, and if the change in zoom level is zooming out, then the updated aggregated tag is aggregated with at least one more tag.

Aggregating tags in images

The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R, A, B, B, G, X, Y, Y, and Yare as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors

Disclosed herein are certain indoloquinolone compounds, methods of preparation thereof, pharmaceutical compositions thereof, and uses thereof, such as their uses as ALK inhibitors.

Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors

Inhibitors of MDM2 and MDM2-related proteins and compositions containing the same are disclosed. Methods of using the MDM2 inhibitors in the treatment of diseases and conditions wherein inhibition of an interaction between p53 and MDM2 provides a benefit, like cancers, also are disclosed.

MDM2 inhibitors and therapeutic methods using the same

9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors

Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.

Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same

Growing community of inventors

Ann Arbor, MI, United States of America

Liu Liu